Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit
This article was originally published in The Gray Sheet
Executive Summary
Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business
You may also be interested in...
Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI
ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December